Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with a history of sino-nasal surgery.

It reported that the FDA evaluated Dupixent under Priority Review for the treatment of AFRS, reserved for medicines that hold the potential to offer considerable improvements in the diagnosis, treatment, or prevention of serious conditions. Management stated that the approval expands Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) indications in sino-nasal diseases to now include AFRS, alongside chronic rhinosinusitis with nasal polyps.

Kenneth Mendez, President and CEO, Asthma and Allergy Foundation of America (AAFA), stated that as the first treatment specifically approved for AFRS, Dupixent offers the potential for relief to adults and children six years and older struggling with potentially debilitating symptoms.

In another development, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 19 the FDA’s acceptance for Priority Review of the Biologics License Application (BLA) for garetosmab to treat adults with fibrodysplasia ossificans progressiva. The target action date for the FDA decision is August 2026. Management stated that garetosmab is a monoclonal antibody that blocks Activin A, a protein discovered by the company to be crucial in the development of heterotopic ossification (HO) lesions in people with FOP.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.